Ongericimab
mAbexperimental
Clinical trial activity
10 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
4
Phase 4
0
Earliest trial started Dec 11, 2017 (NCT04197817)
Timeline
Indications
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594566 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07106034 | Phase 2 | Aug 31, 2025 | Ningxia Medical University, Shanghai Junshi Bioscience Co.,Ltd. |
| NCT05859529 | Phase 1 | May 30, 2023 | Shanghai Junshi Bioscience Co.,Ltd., Sponsor GmbH |
| NCT05621070 | Phase 3 | Dec 2, 2022 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT05532800 | Phase 3 | Feb 28, 2022 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT05128539 | Phase 1 | Dec 31, 2021 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT05325203 | Phase 3 | Dec 31, 2021 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04781114 | Phase 3 | Dec 23, 2020 | People's Liberation Army of China, Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04515927 | Phase 2 | Aug 17, 2020 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04469673 | Phase 1/Phase 2 (Phase 2) | May 23, 2019 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT04197817 | Phase 1 | Dec 11, 2017 | Shanghai Junshi Bioscience Co.,Ltd. |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 10 | 9 | 3 | 2017 |
| Ningxia Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2020 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1